Should You Buy Surgery Partners Inc (SGRY) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Surgery Partners Inc (SGRY) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock's financial performance shows declining net income and EPS, and while there are some positive catalysts like hedge fund buying and potential long-term sector growth, the short-term outlook and technical indicators do not strongly support an immediate buy. Analysts have also lowered price targets, reflecting cautious sentiment. It is better to hold off on investing until clearer positive trends emerge.
Technical Analysis
The MACD is positive and expanding (0.0879), indicating a bullish trend. RSI is neutral at 61.393, and moving averages are converging, showing no strong directional momentum. The stock is trading near its resistance level (R1: 16.31), suggesting limited immediate upside potential.
Analyst Ratings and Price Target Trends
Analysts have lowered price targets across the board, with the latest target from Mizuho being $19 (down from $22) while maintaining an Outperform rating. Other firms like JPMorgan, Barclays, and UBS have also reduced their targets, citing payer mix pressure, volume deceleration, and cautious guidance.
Wall Street analysts forecast SGRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGRY is 26.3 USD with a low forecast of 18 USD and a high forecast of 36 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast SGRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGRY is 26.3 USD with a low forecast of 18 USD and a high forecast of 36 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 14.850
Current: 14.850
